A small molecule called GC4419 administered before intensity-modulated radiotherapy (IMRT) may reduce the duration and incidence of severe oral mucositis (OM) in patients with oral cavity (OC) and oropharyngeal (OP) cancers.
Women with head and neck cancer (HNC) were about twice as likely to die from the disease than from noncancer causes compared with men, according to a retrospective analysis of patients at Kaiser Permanente Northern California using the Generalized Competing Events (GCE) model.
The findings of a pan-cancer study have indicated that all patients with microsatellite instability-high (MSI-H) tumors should be tested for Lynch syndrome, regardless of cancer type or their personal or family history of cancer.
Adding the mutant-selective next-generation PI3K inhibitor taselisib to fulvestrant chemotherapy provides a small but statistically significant increase in investigator-assessed progression-free survival (INV-PFS).
Adjuvant denosumab improved disease-free survival (DFS) and is safe for postmenopausal women receiving an aromatase inhibitor (AI) for the treatment of nonmetastatic breast cancer, according to results from a large European study.
The Allen S. Lichter Visionary Leader Award was first presented in 2017 to honor those who have significantly changed the field of oncology or made outstanding contributions to further the mission of ASCO, CancerLinQ LLC, or Conquer Cancer through leadership and inspiration.
Sunitinib alone was not inferior to cytoreductive nephrectomy (CN) followed by sunitinib with regard to overall survival in a phase III trial of patients with intermediate- and poor-risk metastatic renal cell carcinoma (RCC).
Endocrine therapy (ET) alone was noninferior to ET plus chemotherapy for women with estrogen receptor (ER)−positive, HER2-negative, axillary node−negative, early-stage breast cancer (BC) with a midrange score as measured by the Oncotype DX Breast Recurrence Score gene expression assay.
The combination of capivasertib plus paclitaxel resulted in a significantly prolonged progression-free survival (PFS) compared with paclitaxel alone among women with metastatic, triple-negative breast cancer (TNBC) with alterations in PI3K/AKT/PTEN.
Treatment with the anti-CD19 CAR T-cell therapy axicabtagene ciloleucel (axi-cel) induced durable, high response rates in patients with refractory diffuse large B-cell lymphoma (DLBCL), according to results from the ZUMA-1 trial (Abstract 3003).
A chemotherapy-free combination immunotherapy regimen had similar efficacy as the standard chemotherapy regimen in patients with previously untreated, advanced follicular lymphoma in the phase III RELEVANCE trial (Abstract 7500).
Adding nelarabine to chemotherapy improved 4-year disease-free survival (DFS) and provided an overall survival (OS) of 90% in patients with newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL), according to results from the largest phase III clinical trial to date.